C-QXFTTisento Therapeutics
sGC stimulation, mitochondrial disease
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QXFT
C-QXFTC-QXFTsGC stimulation, mitochondrial disease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to evaluate the long-term safety and tolerability of zagociguat in patients with MELAS who completed study medication treatment in the lead-in study TIS6463-203. TIS6463-204 is evaluating zagociguat in an open-label extension study at the daily dose of 15mg. The study medication is a once daily oral table and will be provided at the clinic and/or shipped to the participant's home. Study assessments will be conducted during clinic visits which will occur at three months and then at six months. Thereafter, clinic visits will occur every six months.
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy male and female elderly participants.
Stage 1: To assess the safety and tolerability of single-ascending-dose levels of IW-6463 tablets when administered orally to healthy subjects Stage 2: To assess the safety and tolerability of multiple-ascending-dose levels of IW-6463 tablets administered orally to healthy subjects Stage 3: To assess the safety and tolerability of a single dose of IW-6463 when administered to health subjects in fed vs fasted states and explore the effects of food on IW-6463 pharmacokinetics (PK)
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
%PDF-1.7 %���� 1 0 obj >/Metadata 361 0 R/ViewerPreferences 362 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 12 0 R 13 0 R 14 0 R] /MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][s�8�~OU� �-�!$w]�� g.��dc����>02eq"K ��'�ן�$%�N �����"�����u�zuR7ռ�5��ѫ��)f��*��������.�ܖ���ժh���������/���>>N_���������?_��:�$H�$�T��GY�����#XA�Pĉ�0�i�� ����(��vO���/^�+�" ^����E���,�:��$Wa��L�xc���K��������ZGЗ��� ���� %�s"Jf�^Hm��e]�_*-��w2�P�L�K&|�d��p˥��y���c�����P … 93>> startxref 262639 %%EOF 361 0 obj >stream Microsoft® Word for Microsoft 365 application/pdf Microsoft® Word for Microsoft 365 2024-12-20T13:18:56+01:00 2024-12-20T13:22:06+01:00 2024-12-20T13:22:06+01:00 uuid:9EB069B8-AA8C-4BB9-BFF8-A9E14C5B0D78 uuid:0e45ab91-4e49-424e-af1a-9236a0d2c624 endstream endobj 364 0 obj > endobj xref 0 1 0000000000 65535 f 361 1 0000262823 00000 n 364 1 0000266308 00000 n trailer ]/Prev 262639>> startxref 266498 %%EOF
Cyclerion Therapeutics, Inc. SEC 10-Q Report — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Cyclerion Therapeutics, Inc. SEC 10-Q Report Cyclerion Therapeutics, Inc. SEC 10-Q Report 2 min read CYCN Cyclerion Therapeutics, Inc., a biopharmaceutical company focused on the development of treatments for serious central nervous system diseases, has released its Q3 2024 10-Q report. The report provides a comprehensive overview of the company's financial performance and key business activities during the quarter, highlighting significant str … Interest Income : $0.031 million, decreased by 50% due to a lower money market fund balance. Gain from Insurance Recovery : $1.317 million, contributing significantly to the reduction in net loss. Business Highlights Strategic Focus on TRD : Cyclerion has prioritized an individualized therapy for treatment-resistant depression (TRD) as its foundational product candidate, entering into a non-binding option to license agreement for the associated intellectual property. The com
Cyclerion Therapeutics, Inc. SEC 10-Q Report — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Cyclerion Therapeutics, Inc. SEC 10-Q Report Cyclerion Therapeutics, Inc. SEC 10-Q Report 2 min read CYCN Cyclerion Therapeutics, Inc., a biopharmaceutical company focused on the development of treatments for serious central nervous system diseases, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and key business developments during the period. … % compared to the same period in 2024, attributed to a decrease in money market fund balance and reduction in interest rates. Gain from Insurance Recovery : The company recognized a gain of $1.317 million from insurance recovery related to the loss of advanced intermediated GMP finished materials during the nine months ended September 30, 2025. Business Highlights New Product Launches : Cyclerion has prioritized an individualized therapy for treatment-resistant depression (TR
News and Events | Reagan-Udall Foundation Skip to main content About Board of Directors Our Staff Annual Reports Policies Fellowship Careers Projects Column 1 Advancing Regulatory Science Oncology Multi-Regional Clinical Trials Rare Disease Innovation Roundtable Animal Health & Veterinary Medicine Antimicrobial Use in Food Animals Cross-Sectoral Health Threats Industry SWOT Analysis Expanded Access E-request App Navigator Resources for COVID-19 FDA Patient Listening Sessions Column 2 Food & Nutrition About Food Traceability Healthy Rule Roundtables Nutrition Facts Label Produce Safety … pdown trigger Search About Board of Directors Our Staff Annual Reports Policies Fellowship Careers Projects Column 1 Advancing Regulatory Science Oncology Multi-Regional Clinical Trials Rare Disease Innovation Roundtable Animal Health & Veterinary Medicine Antimicrobial Use in Food Animals Cross-Sectoral Health Threats Industry SWOT Analysis Expanded Access E-request App Navigator Resources for COVID-19 FDA Patient Listening Sessions Column 2 Food & Nutrition About Fo … s. Read More Tuesday, April 14, 2026 Friends of Cancer Research: Meeting Recap: Application of External Control Arms in Oncology Drug Development Moderator Michael McCaughan and Dr. Amy Abernethy kicked off the fireside chat by reflecting on the evolution of RWD, including prior efforts such as the Friends RWD Pilot 1.0 Project and the COVID-19 Evidence Accelerator led by Friends and the Reagan-… Read More Thursday, April 09, 2026 PF Warriors: Patients, Caregivers, Doctors Me … e Magazine: Produce Safety Alliance Receives Reagan-Udall Foundation Leadership Award The Reagan-Udall Foundation for the FDA honored the Produce Safety Alliance (PSA) with the Reagan-Udall Foundation Leadership Award, one of its 2025 Innovations in Regulatory Science & Policy awards, at a Dec. 9 ceremony in Washington, D.C. Read More Monday, December 29, 2025 Clinical Leader: FDA Further Expands And Clarifies Expanded Access FAQs The guidance includes new information to … ur received the American Association for Cancer Research (AACR) Enduring Impact Award for Transformative Service to Cancer Science and Medicine, a recognition of his profound influence on oncology research and policy. His honors also… Read More Tuesday, November 11, 2025 Food Safety Magazine: Regan-Udall Report Supports FDA Infant Formula Safety
Cyclerion pivots to TRD therapy amid going-concern risk | CYCN Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cryp … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … 226; we are currently preparing a new potential product candidate for potential application in patients suffering from treatment resistant depression and we may not be successful in acquiring all license and other rights necessary to develop this technology, establish and successfully complete clinical studies, obtain necessary regulatory governmental approvals and successfully commercialize this product candidate; • there is substantial doubt regarding our ability to c … through potential license agreements, which, if realized, would be used to help fund our strategic building plan and provide value to our stockholders. The following table is a high-level summary of our historical sGC portfolio:   Program Indication(s) Description Status Zagociguat (CNS-penetrant) MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome), cognitive impairment associated with schizophrenia, and Alzheimer's Disease w … erion Competing Product”) anywhere in the world, or (ii) license, convey, grant, or otherwise transfer any rights to any third party to initiate IND-enabling preclinical development, develop, commercially manufacture, commercialize, or otherwise exploit a Cyclerion Competing Product anywhere in the world. On January 27, 2025, Tisento Therap
CORRESP 1 filename1.htm CORRESP 245 First Street Riverview II, 18th Floor Cambridge, MA 02142 (857) 327-8778 [email protected] cyclerion.com December 12, 2023 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington D.C. 20549 Attn: Ms. Li Xiao and Ms. Angela Connell Re: Cyclerion Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 22, 2023 Form 10-Q for the Quarterly Period Ended September 30, 2023 Filed November 13, 2 … act of the VIE. Refer to CG 5.8 for further discussion related to the application of the related party tiebreaker test. If no single party within the related party group has stated power, and a VIE’s significant activities require the consent of two or more related parties, a reporting entity must assess whether power is shared. As discussed in CG 5.2.4, shared power exists only when the unanimous consent of all parties believed to share power over … teristics in paragraph 810-10-25-38A, the single decision maker shall apply the guidance in paragraph 810-10-25-44 only when the single decision maker and one or more of its related parties are under common control and, as a group, the single decision maker and those related parties have the characteristics in paragraph 810-10-25-38A. This guidance is also not applicable. As discussed above in the discussion of ASC 810-10-25-42, there is no … t met. Because both criteria (a) and (b) above have to be met for the application of the guidance in ASC 810-10-25-44B and criteria (a) has not been met, Cyclerion concluded that it should not consolidate Tisento under the VIE model. d. Provide us with a copy of the Asset Purchase Agreement to assist us with our review. The Asset Purchase Agreement is available on EDGAR as Exhibit 10.3 to the second quarter 10-Q filed with the SEC on July 28, 2
Peter Hecht Bio — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices I
10-K 0001755237 FY false http://fasb.org/us-gaap/2024#QualifiedPlanMember 0001755237 cycn:LicenseAgreementMember 2023-01-01 2023-12-31 0001755237 us-gaap:SeriesAPreferredStockMember 2023-03-31 0001755237 2025-02-28 0001755237 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001755237 us-gaap:CommonStockMember 2023-03-31 0001755237 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001755237 us-gaap:DomesticCountryMember 2023-12-31 0001755237 2024-12-31 0001755237 cycn:WorkforceReductionsMember 2024-01-01 2024-12-31 0001755237 cycn:WorkforceReductionsMember … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … s with the goal of generating revenues which, if realized, will be used to help fund our strategic building plan and provide value to our stockholders. The following table is a high-level summary of our historical sGC portfolio:   Program Indication(s) Description Status Zagociguat (CNS-penetrant) MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome), cognitive impairment Zagociguat is a CNS-penetrant sGC stimulator that has sh … erion Competing Product”) anywhere in the world, or (ii) license, convey, grant, or otherwise transfer any rights to any third party to initiate IND-enabling preclinical development, develop, commercially manufacture, commercialize, or otherwise exploit a Cyclerion Competing Product anywhere in the world. 7   On January 27, 2025, Tisento Therapeutics announced that the first patient has been dosed in its global Phase 2b PRIZM study. The study is investigating the i … eaty (PCT) that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in each of the 157 contracting states, followed by the process of entering national phase, which requires a separate application in each of the member states in which national patent protection is s
Publications & Presentations — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS
Our Science — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices Inter
Data — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices Interview St … the Parties have agreed to comply with these Jurisdiction Specific Terms which apply to the extent that the Parties Process Tisento Personal Data originating from, or protected by, Applicable Data Protection Laws in one of the jurisdictions identified herein. 1. Bulgaria 1.1. Wherever the Processing pursuant to the Addendum falls within the scope of Bulgaria’s Personal Data Protection Act (as amended in November 2019) (“ PDPA ”), or any ot … regulations, or guidance, the provisions of the Addendum and this Section shall apply to such Processing. 1.2. The Parties agree and acknowledge that, when Service Provider acts as a Processor, Service Provider shall comply with Article 25a of the PDPA which requires Service Provider to: (a) Return to Tisento any Personal Data Processed pursuant to the Addendum within a period of one month after having become aware of any Personal Data that has been di … rom Tisento to Service Provider, one of the following transfer mechanisms shall apply, in the following order of precedence: (a) A valid adequacy decision adopted by the European Commission on the basis of Article 45 of the GDPR. (b) The appropriate Standard Contractual Clauses adopted by the European Commission from time to time. (c) Any other lawful data transfer mechanism, as laid down in EEA Data Protection Laws, as the case may b … bit A . v. The Parties agree to apply the following module[s]: (A) With respect to any Controller-to-Processor Restricted International Transfers, the Parties agree to implement Module Two of the EU 2021 Standard Contractual Clauses. (B) With respect to any Processor-to-Controller Restr
Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices Interview Study Additiona
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
10-Q Q1 false --12-31 0001755237 0001755237 cycn:KorsanaBiosciencesIncMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-01 0001755237 2023-07-28 2023-07-28 0001755237 us-gaap:PreferredStockMember 2025-03-31 0001755237 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001755237 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001755237 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001755237 us-gaap:PerformanceSharesMember 2025-01-01 2025-03-31 0001755237 us-gaap:ResearchAndDevelopmentExpenseMember 2026-0 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … we continue to progress the development of our product candidate for potential application in patients suffering from treatment resistant depression, we may not be successful in acquiring all license and other rights necessary to develop this technology, establish and successfully complete clinical studies, obtain necessary regulatory governmental approvals and successfully commercialize this product candidate; • there is substantial doubt regarding our ability to cont … his analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made and, except as required by applicable law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.   5   Cyclerion Therapeutics, Inc. Condensed Consolida ted Balance Sheets (In thousands except share and per share data) ( … r to Guggenheim Securities, acting as the Company’s agent, subject to the application of General Instruction I.B.6 of Form S-3 (“Instruction I.B.6”) pertaining to primary offerings by certain registrants, including the Company. The Company has provided Guggenheim Securities with customary indemnification rights, and the Company
Tisento Therapeutics | Venrock Job Board Venrock Companies People 1.0 Search jobs Explore companies Join talent network Talent My job alerts Tisento Therapeutics tisentotx.com Locations Cambridge, MA, USA · Cambridge, MA, USA industry Health Care · Medical · Therapeutics Size 11 - 50 employees Stage Series A founded in 2023 Socials LinkedIn Crunchbase Facebook About Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs. Something looks off? Open jobs at Tisento Therapeutics This company does not have jobs relevant to this job boa
Tisento Therapeutics’ Chad Glasser Discusses PRIZM Trial, Zagociguat Development for MELAS – Rareatives Skip to content Instagram X Search Rareatives About Blog Contact Resources World Orphan Drug Congress MELAS Tisento Therapeutics’ Chad Glasser Discusses PRIZM Trial, Zagociguat Development for MELAS Tisento Therapeutics is developing zagociguat for MELAS, addressing unmet treatment needs through a patient-centric clinical trial design. Jessica Lynn April 29, 2026 8–13 minutes clinical trial , drug development , EL-PFDD , MELAS , mitochondrial disease , rare disease , rare diseases , Ti … s, and other aspects of their lived experience. “They can share live testimony, submit comments, and respond to polling questions and surveys,” says Glasser. “We sponsored the event because it’s important to educate the FDA and other drug developers. MitoAction did a fantastic job. And, in terms of the content, the heartbreaking stories were tough to hear but reminded us why we do what we do and how significant the unmet needs are.” Beyond serving as a reminder for the many b … erck), and before that, he completed a two-year post-doctoral clinical research fellowship and started his career at Cubist Pharmaceuticals (acquired by Merck). Chad’s thoughtful, calm, and data-driven approach to problem-solving allows him to overcome the complex and seemingly insurmountable challenges of rare disease drug development. Within each stakeholder relationship, whether it be a physician, a regulator, or a patient advocate, Chad strives to maintain the highest deg
Skip to main content VCbacked Search Digest YC Research Log in Get Started Home / Directory / Investors / Polaris Partners Back to Investors Polaris Partners Portfolio Companies Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds. Last updated: June 2026 Polaris Partners Investment Overview Portfolio Companies 130 Total Invested $3.9B Average Investment $46.1M What Industries Does Polaris Partners Invest In? Biotechnology 12 Health Care 12 Medical 7 Therapeutics 5 Wellness 3 Artificial Intelligence (AI) 2 Predictive Analytics 2 … rting any fuel to electricity via light. Somerville, United States January 2026 Grant Founder Contacts [email protected] [email protected] 19,000+ verified contacts Get Instant Access Muna Therapeutics Biopharma Biotechnology Medical Pharmaceutical Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's. Copenhagen, Denmark January 2026 $1.0M Grant Founder Contacts [email protected
Instagram Instagram Log In Sign Up Close Never miss a post from tisentomilano Sign up for Instagram to stay in the loop. Sign up Log in tisentomilano • Follow More options tisentomilano 8w Get inspired by this classic silver look, perfect for wedding season. #tisento #modernclassic #wedding Load more comments aliya.st 8w 🔥🔥🔥 1 like Reply Like Comment 1 Share Save April 27 Log in to like or comment. More posts from tisentomilano Carousel Carousel Carousel Carousel Carousel Carousel Carousel Carousel Carousel See more posts Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagr
Chad Glasser Bio — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices … erck), and before that, he completed a two-year post-doctoral clinical research fellowship and started his career at Cubist Pharmaceuticals (acquired by Merck). Chad’s thoughtful, calm, and data-driven approach to problem-solving allows him to overcome the complex and seemingly insurmountable challenges of rare disease drug development. Within each stakeholder relationship, whether it be a physician, a regulator, or a patient advocate, Chad strives to maintain the highest deg
Publications & Presentations — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS
Tisento Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Tisento Therapeutics, Inc. Holding Company | 2023 | Massachusetts, United States | 10-50 | www.tisentotx.com Holding Company | 2023 | Massachusetts, United States | 10-50 | www.tisentotx.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Congenital Disorders Nervous System Diseases Endocrinology and Metabolic Disease Small molecule drug Disease d … rvous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.” Cyclerion and Akebia have re-negotiated a mutually beneficial a … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Tisento Therapeutics Raises $81M in Series A | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real Estate Healthcar
Tisento Launches with $81 Million From Top-Tier Investor --> Accessibility: Skip TopNav Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets July 31, 2023 07:00 ET | Source: Cyclerion Therapeutics, Inc. Cyclerion Therapeutics, Inc. – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July
SciThera - Venrock You need to enable JavaScript to run this app.
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account January 08, 2026 07:00 ET | Source: Tisento Therapeutics Inc Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS Tisento's global Phase 2b PRIZM study, which is evaluating zagociguat for the treatment of the rare mitochondrial disease MELAS, is fully enrolled November 03, 2025 07:00 ET | Source: Tisento Therapeutics Inc Tisento Therapeuti
Sanofi Ventures | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Sanofi Ventures Sanofi Ventures is the corporate venture capital arm of Sanofi. It invests in early-stage biotech and digital health companies of strategic interest to Sanofi, providing capital from seed through Series B and beyond while offering portfolio companies access to Sanofi expertise across science, development, regulatory, data analytics, manufacturing, market access and commercialization. The team leads financings, serves on boards, and aims to suppo
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.2 Nature of Business 6 Months Ended Jun. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract]   Nature of Business 1. Nature of Business Nature of Operations Cyclerion Therapeutics, Inc. (“Cyclerion”, the “Company” or “we”) is a biopharmaceutical company on a mission to develop treatments for serious diseases. Our portfolio includes novel soluble guanylate cyclase ("sGC") stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (
Home | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 Early-stage biotech and digital health investors We are a strategic venture fund Our raison d' ê tre We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach We invest in top-tier biotech and digital health companies … SDAQ: CAMP), where she was the Founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at MIT. During her time at MIT, Paulina founded the MIT Postdoctoral Association and served as its President. Paulina also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina Unive … ogy and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team. Christopher Gagliardi Christopher Gagliardi Principal Close connect Christopher Gagliardi Principal Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting where his work focused on corporate strategy, du … ics. He also led Sanofi Ventures’ investment in Curevo. Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University. Meg Krench Meg Krench Principal Close connect Meg Krench Principal Meg joined Sanofi Ventures in 2021 with a background in biotech investing and business development. She previously worked as part of … vation team at Vertex Pharmaceuticals and at RA Capital, a crossover investment fund. Meg currently serves as a director for Normunity and as an observer for several companies including Draig Therapeutics, Eligo Bioscience, Korsana Biosciences, Quralis, and a stealth immunology company. Meg also supported Sanofi Ventures’ investment in Aliada The
We’re pleased that Kristin Lurk has... - Tisento Therapeutics Facebook Log In Tisento Therapeutics's Post Tisento Therapeutics May 21 · Shared with Public We’re pleased that Kristin Lurk has joined our team as executive director of program management! Kristin is a strategic biotech program management leader with deep expertise leading complex, cross-functional drug development programs from preclinical through Phase 3 and pre-commercial launch. She is passionate about continuously learning and bringing clarity and collaboration to every program she has the opportunity to work on. Welcome,
Portfolio | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 Our Portfolio IPO / Acquired Investments Biotherapeutic Digital Health All abcuro Close Private Newton, MA www.abcuro.com Developing treatments for autoimmune and cancer indications. Abcuro is a biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008 toward the clinic, a first-in-class anti-KLRG1 … ence. Press releases Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Jan 10, 2022 Read More Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform. Mar 25, 2021 Read More Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health Jul 01, 2020 Read More Evidation Health and BARDA Partner on Early Warning System for COVID-19 Jun 04, 2020 Read More Evidation … erited Metabolic Disorders Jul 29, 2014 Read More Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders Jun 30, 2014 Read More Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium Jun 05, 2014 Read More Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients … eutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund Apr 09, 2020 Read More Icosavax Close Acquired Seattle www.icosavax.com Focusing on developing safe and effective vaccines against infectious diseases. Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like parti … res $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support. Feb 25, 2021 Read More Minervax Close Private Copenhagen, Denmark minervax.com Developing a prophylactic vaccine against Group B Streptococcus. Minervax is a clinical stage biotechnology company developing a prophylactic
Bryan Roberts Bio — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices
Marta Cavero Tomas Bio — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient V
Paulina Hill Bio — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices … herapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab at MIT. Paulina completed her PhD in Molecular Medicine from Wake Forest School of Medicine. Tisento Therapeutics 245 First Street, Riverview II, 18th Floor Cambridge, MA 02142 [email protected] © 2023-2024 — all rights reserved Privacy Notice | Terms of Use | Expanded Access | Cookie Notice
About Us — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices Intervie
Skip to main content How it works Pricing System map Explore Metro Boston Income Eligible Help Log In Join EN Join Group Membership Partners Below is the full, current list of Bluebikes Group Membership Partners. Your group, company or organization can join too! Enroll your company Platinum Partners Organization pays $101.50 annually per member who signs up, and member pays $0. Usage fees are covered by the organization. Actus Bio, Inc. Consulate General of Canada Merida Biosciences Samuels & Associates Gold Partners Organization pays $101.50 annually per member who signs up, and member pa
TI SENTO — Access 0 Skip to Content About About Access About the CMJ Visit Why Visit? Exhibitor Profiles FAQ's Code of Conduct Register Contact REGISTER Open Menu Close Menu Open Menu Close Menu About About Access About the CMJ Visit Why Visit? Exhibitor Profiles FAQ's Code of Conduct Register Contact REGISTER Folder: About Back About Access About the CMJ Folder: Visit Back Why Visit? Exhibitor Profiles FAQ's Code of Conduct Register Contact REGISTER TI SENTO Silver Jewellery Branded Jewellery 23 Jan Written By Inspired by classic shapes but never old-fashioned. Created for a lifetime an
Just 48 hours until #MitoMed 2026! Today, Andy Dearth, UMDF’s Director of Marketing, Communications, and Advocacy, shares what he's most looking forward to at this year's conference. Tag someone you're excited to reconnect with at MitoMed in the comments! | United Mitochondrial Disease Foundation
@euromit-2026.bsky.social on Bluesky JavaScript Required This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is. Learn more about Bluesky at bsky.social and atproto.com . Profile Euromit-2026 euromit-2026.bsky.social did:plc:gwgvuc6b3gcayp4szzhhadtb Euromit 2026, the international congress dedicated to mitochondrial diseases research will take place in #Angers, France from May 30 to June 4, 2026 : cutting-edge science, clinical updates and networking. Visit website : https://www.euromit2026.eu/
Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS January 8, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Company Expects to Report Topline Data in Q4 2026 CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tisento Therapeutics … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS January 27, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Patient-Centered PRIZM Study Measures Impact of Once-Daily Oral Zagociguat on Fatigue and Cognitive Impairment, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sear … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program October 25, 2023 | 4 min read Twitter LinkedIn Facebook Email Print Tisento Therapeutics today announced the initiation of a patient i … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS June 17, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Global Phase 2b PRIZM Study of Zagociguat is Currently Enrolling Participants with MELAS CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) … 3 min read · Heather McKenzie FDA REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot June 22, 2026 · 3 min read · Heather McKenzie BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs N … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram Instagram Log In Sign Up Close Never miss a post from breojewellers Sign up for Instagram to stay in the loop. Sign up Log in breojewellers • Follow More options breojewellers 264w Ti Sento Milano disc pendants are a jewellery staple 🗝💫 These pendants are extremely subtle and beautiful, sure to finish off any outfit... . Available in; Mother of pearl- €129 Two tone (gold & silver)- €119 Silver- €99 . Engraving is also available on the two tone & silver pendant for that finishing touch 🤍 . . . . #tisentomilano #tisento #sterlingsilver #silverjewellery #silver #gold #mothero
Instagram Instagram Log In Sign Up Close Never miss a post from mesmeric_distribution Sign up for Instagram to stay in the loop. Sign up Log in mesmeric_distribution • Follow More options mesmeric_distribution 96w Thank you Professional Jeweller Magazine for featuring TI SENTO as a “Top Exhibitor” in your August Issue at the forthcoming Jewellery Show - stand C20. @tisentomilano @professionaljeweller @jewelleryshowuk @mesmeric_distribution #aw24 #tisento #mesmericdistribution Load more comments No comments yet. Start the conversation. Like 9 Comment Share Save August 19, 2024 Log in to like or
#mitomed #mitochondrialdisease #melas #wehearyou | Tisento Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement
We are proud to support... - Tisento Therapeutics Facebook Log In Tisento Therapeutics's Post Tisento Therapeutics March 19 · Shared with Public We are proud to support #euromit2026 as a Silver Sponsor! We look forward to connecting with other scientists, clinicians, and professionals dedicated to advancing the care and understanding of mitochondrial diseases. Visit our booth! #WeHearYou All reactions: 2 1 share Like Comment
Welcome back,... - United Mitochondrial Disease Foundation Facebook Log In United Mitochondrial Disease Foundation's Post
zagociguat (CY6463) / Tisento Therap zagociguat (CY6463) / Tisento Therap - LARVOL DELTA Home Next Prev 1 to 25 Of 42 Go to page 1 2 December 16, 2025 PRIZM: A Phase 2b Study of Zagociguat in Patients With MELAS (clinicaltrials.gov) - P2 | N=44 | Active, not recruiting | Sponsor: Tisento Therapeutics | Recruiting ➔ Active, not recruiting Enrollment closed • Cardiovascular • CNS Disorders • Metabolic Disorders Print Email More sharing Reddit StumbleUpon Delicious October 16, 2025 PRIZM: A Phase 2b Study of Zagociguat in Patients With MELAS (clinicaltrials.gov) - P2 | N=44 | Recruiting | Sponsor
Terms of Use — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices Inte
Error Facebook Facebook is not available on this browser To continue using Facebook, get one of the browsers below. Learn more English (US) + Meta © 2026
PRIZM Clinical Trial — Tisento Therapeutics .popup .popuptext { z-index: 999; } 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochond
Privacy Policy — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices In
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Tisento Therapeutics’ Patient-Informed Phase 2 Trial is Advancing MELAS Research – Rareatives Skip to content Instagram X Search Rareatives About Blog Contact Resources World Orphan Drug Congress MELAS , mitochondrial disease Tisento Therapeutics’ Patient-Informed Phase 2 Trial is Advancing MELAS Research Mitochondrial diseases, especially MELAS, present significant challenges due to their complexity and lack of approved treatments. Tisento Therapeutics aims to develop zagociguat to address MELAS symptoms through the ongoing Phase 2b PRIZM trial. Their patient-centered approa
Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mi
Tisento Therapeutics on PRIZM trial for MELAS | Jessica Lynn posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linke
Tisento Therapeutics identifies new sGC activators | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-ene
Tisento Therapeutics Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib mark
Mitochondrial Diseases — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient V
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS — Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: A
Tisento Therapeutics 0 Skip to Content About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu About Us Our Mission Team Board Network Contact Mitochondrial Diseases MELAS Patient Voices Interview Study Additional Resources Our Science Zagociguat Publications PRIZM MELAS Study News Open Menu Close Menu Folder: About Us Back Our Mission Team Board Network Contact Folder: Mitochondrial Diseases Back MELAS Patient Voices Interview Study Additiona
Mito Champion Spotlight - UMDF Mitochondrial Disease Resources Medications Insurance Assistance Forzinity Kygevvi Get Involved Research About Us Donate Donate Now Energy for Life Family Tribute Pages Match Your Gift Get Support Latest News -Mito Champion Spotlight UMDF Names Award Winners for 2024 Jul 12, 2024 From Left to right: Fatema Shikora with Jennifer Chickering of Tisento Therapeutics, Jared Goettemoeller with Dr. Tyler... Read more Meet Vera Johnson Apr 22, 2024 By all appearances, 10-year-old Vera Johnson of Minnesota seems very much like her peers. She lives lif … se of your cells. I didn’t really... Read more 2021 Stanley A. Davis Leadership Award Winners – Ann and Howard Korsen Jun 26, 2021 The Stanley A. Davis Leadership Award is presented annually to a UMDF leader who exemplifies dedication to the UMDF. The award was created to... Read more 2021 Energy Award Winner – Sebastien Cotte Jun 26, 2021 The Energy Award is designed to recognize an individual who embodies the spirit of the UMDF and its Mission: promoting researc … e UMDF and its Mission: promoting research and education... Read more 2021 LEAP Award Winner – Lily Finnigan Jun 26, 2021 We are proud to recognize Lily Finnigan of Salt Lake City, UT, as the 2021 LEAP Award recipient. Lily has battled Mito Complex-1 for nearly 18... Read more 2021 Heartstrings Award Winner – Jackson Adams Jun 26, 2021 The Heartstrings Award recognizes a child or teen that has donated or raised funds for the UMDF, enabling the UMDF to continue its … Read more Powerhouse Podcast Episode #5 – An interview with UMDF Vanguard Award Winners Jun 25, 2021 Powerhouse Podcast Episode #5 Join UMDF President and CEO Brian Harman and Science and Alliance Officer Philip Yeske, Ph.D. as they catch up... Read more Page 1 of 4 1 2 3 4 » Last Updated: Jun 24, 2021 @ 9:19 am Search for: Categories About Mito Conference Research News Position Statements Corporate Partner Fundraising Mito Champion Spotlight Donor Spotlight Recent Post … ht Donor Spotlight Recent Posts UMDF and Mito Foundation Announce 2026 Research Grant Program Award Winners June 2026 Newsletter: Time for Mito Med 2026 May 2026 Newsletter: Support Our Spring Appeal Ask the Mito Doc – May 2026 Mission of UMDF To promote research and education for the diagnosis, treatment and cure of mitochondrial disorders
Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease November 4, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Findings Demonstrate the Importance of Addressing Both Fatigue and C … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Energy in Action Podcast Episode 135: How Tisento is Advancing Mitochondrial Research - MitoAction Facebook Instagram Twitter Get Support – Call 1-888-MITO-411 Shop Events Donate Search MitoAction Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease Mitochondrial Disease About Mito New Patient Kit Types of Mitochondrial Diseases Symptoms of Mito Treatment for Mito Diagnosing Mito Mito FAQs Mito in the News Diagnosis & Care Mitochondrial Disease Diagnosis Find a Mito Doctor Mito Disease Treatment Mito Cocktail Clinical Trials & Stud … h Packages Liney’s Lovies MitoAction Programs Dalia’s Wish Matthew Harty Camper Fund & Scholarship Marcel’s Way Family Fund MitoArtisan’s Playtime MitoSantas MyMito App Education Monthly Expert Series Wondering Wednesdays Energy In Action Podcast Energy 4 Education Patient Education Forums International Metabolic Conference Planning & Preparation Health Insurance Disability Benefits Mobility Devices Vehicle Modification Estate Planning Medical Child Abuse Join the Ca … Energy Walks Sandra K. Russell Derby Day Benefit for Mito Matthew Harty Camper Fund Events Team MitoAction! Volunteer Host a MitoSocial Host a MitoPlaydate Create a Fundraiser Become a MitoChampion Share Your Ideas Raise Your Voice Externally Led Patient-Focused Drug Development Meetings Take Legislative Action Mitochondrial Disease Awareness Week Open Mito Mic & Art Show MitoAction Memories About MitoAction Contact Us Connect on Social Our Staff Meet Our Partners Newsl
Upcoming Events - Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets Factor This Power Engineering Live Events DTECH® Events POWERGEN™ INFOCAST Events Calendar Webinars Podcasts Factor This This Week in Cleantech Factor This Policycast Contribute Content Solar Community Residential Utility Scale Wind Power Offshore Turbines & Equipment Power Grid Distribution Grid Modernization Microgrids Outage Management Smart Grids Transmission Hydropower Dams & Civil Structures Small Hydropower Technology & Equipment Tidal & Wave Energy Energy
Tisento’s MELAS treatment receives fast track status from FDA Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social M
Tisento doses first subject in Phase IIb study of zagociguat for MELAS treatment Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Catego … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Newsletter Signup Send Tips Webinars eBooks Open navigation MedCity News Toggle Search Close navigation News Health Tech BioPharma Devices & Diagnostics Consumer / Employer Contributors MedCity Influencers Events Bullseye INVEST Digital Health Podcasts Research Newsletters Newsletter Signup Send Tips Webinars eBooks Twitter Facebook TikTok YouTube LinkedIn RSS Subscribe via email Search for: Search BioPharma, Pharma Bio Startup Ti … The company’s independent board of directors unanimously turned down that proposal. This past March, in its report of 2022 financial results, Cyclerion reported a cash position totaling just $13.4 million. In May, Cyclerion announced a deal to sell zagociguat and another asset, the preclinical CY3018, for $8 million cash and another $2.4 million to cover employee and development expenses for zagociguat. Cyclerion also received a 10% equity stake in Tisento as well as th
Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases May 15, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Tisento to Present at the “Primary Mitochondrial Diseases” Therapeutic Development Workshop Hosted by the Reagan-Udall Foundation for t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease - MitoAction Facebook Instagram Twitter Get Support – Call 1-888-MITO-411 Shop Events Donate Search MitoAction Support, Education, Outreach and Advocacy for Children and Adults Living with Mitochondrial Disease Mitochondrial Disease About Mito New Patient Kit Types of Mitochondrial Diseases Symptoms of Mito Treatment for Mito Diagnosing Mito Mito FAQs Mito in the News Diagnosis & Care Mitochondrial Disease Diagnosis … h Packages Liney’s Lovies MitoAction Programs Dalia’s Wish Matthew Harty Camper Fund & Scholarship Marcel’s Way Family Fund MitoArtisan’s Playtime MitoSantas MyMito App Education Monthly Expert Series Wondering Wednesdays Energy In Action Podcast Energy 4 Education Patient Education Forums International Metabolic Conference Planning & Preparation Health Insurance Disability Benefits Mobility Devices Vehicle Modification Estate Planning Medical Child Abuse Join the Ca … Energy Walks Sandra K. Russell Derby Day Benefit for Mito Matthew Harty Camper Fund Events Team MitoAction! Volunteer Host a MitoSocial Host a MitoPlaydate Create a Fundraiser Become a MitoChampion Share Your Ideas Raise Your Voice Externally Led Patient-Focused Drug Development Meetings Take Legislative Action Mitochondrial Disease Awareness Week Open Mito Mic & Art Show MitoAction Memories About MitoAction Contact Us Connect on Social Our Staff Meet Our Partners Newsl
Where Are They Now Ironwood Pharmaceuticals Get more Life Science Leader insight with our FREE newsletter. sign me up Log In or Subscribe Home Magazine Past Issues Digital Edition Articles Executive Interviews Companies To Watch Where Are They Now Industry Leader CEO Corner Ask The Board Key Topics Clinical Trials Finance-Funding Outsourcing Regulatory Research & Development Business of Biotech Podcast Article | October 31, 2024 Where Are They Now? Ironwood Pharmaceuticals Source: Life Science Leader By Ben Comer , Chief Editor, Life Science Leader Then : In 2016, when former Life Science … stinal diseases, and on growing Linzess sales. Ironwood is currently pursuing a rolling NDA (with final submission expected in the first quarter of 2025) for apraglutide, a once-weekly GLP-2 analog targeting short bowel syndrome. Apraglutide arrived via an acquisition of VictivBio in 2023, following Ironwood’s decision in 2020 to end development of its GERD asset, IW-3718, after disappointing Phase 3 trial results — not the blockbuster potential the company had an